Centre Jean Perrin
Clermont-Ferrand, France
52 recruiting
Showing 1–20 of 71 trials
Recruiting
Not Applicable
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Hepatocellular CarcinomaMetastatic Colorectal CancerNeuroendocrine Tumors+2 more
UNICANCER330 enrolled29 locationsNCT05443087
Recruiting
Phase 3
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Early Breast CancerPremenopausal Breast CancerHR+/HER2- Breast Cancer
UNICANCER3,380 enrolled105 locationsNCT07106632
Recruiting
Phase 3
Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
Squamous Cell Carcinoma of Head and Neck
UNICANCER102 enrolled26 locationsNCT04747054
Recruiting
Phase 2
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals120 enrolled27 locationsNCT06769698
Recruiting
Phase 3
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled150 locationsNCT07225946
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 2
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Triple-Negative Breast Cancer
UNICANCER354 enrolled44 locationsNCT06078384
Recruiting
Not Applicable
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)
Triple-Negative Breast Cancer
Institut Curie450 enrolled13 locationsNCT06225505
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled144 locationsNCT07213674
Recruiting
Phase 3
Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers
Radiotherapy, AdjuvantOral Cavity CarcinomaFlap+1 more
Centre Francois Baclesse348 enrolled30 locationsNCT06798922
Recruiting
Phase 2
Skipping Hormone Therapy in Low-Risk Early Breast Cancer
Breast Cancer (Early Breast Cancer)
UNICANCER700 enrolled41 locationsNCT07661927
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled555 locationsNCT06492616
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled352 locationsNCT06065748
Recruiting
Phase 3
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
Colorectal, Cancer
Canadian Cancer Trials Group834 enrolled55 locationsNCT07152821
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer+1 more
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2,295 enrolled211 locationsNCT05945732
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled77 locationsNCT04585750
Recruiting
Phase 3
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
Thyroid CancerIntermediate Risk
Centre Francois Baclesse368 enrolled29 locationsNCT04290663
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 2
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
Neuroendocrine TumorsProgressive DiseaseIntestinal Well Differentiated Endocrine Tumor
Institut du Cancer de Montpellier - Val d'Aurelle146 enrolled28 locationsNCT04954820
Recruiting
Phase 2Phase 3
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib
Ovarian CarcinosarcomaEndometrial Carcinosarcoma
ARCAGY/ GINECO GROUP138 enrolled36 locationsNCT03651206